Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
Double-blind
Giant cell arteritis
Phase II trial
Placebo
Secukinumab
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
17 Aug 2021
17 Aug 2021
Historique:
received:
23
06
2020
accepted:
06
08
2021
entrez:
18
8
2021
pubmed:
19
8
2021
medline:
20
8
2021
Statut:
epublish
Résumé
One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and maintenance of remission with the monoclonal anti-IL-17A antibody secukinumab. Inhibition of IL-17A could therefore represent a potential new therapeutic option for the treatment of GCA. This is a randomized, parallel-group, double-blind, placebo-controlled, multi-center, phase II study in which patients, treating physicians, and the associated clinical staff as well as the sponsor clinical team are blinded. It is designed to evaluate efficacy and safety of secukinumab compared to placebo in combination with an open-label prednisolone taper regimen. Patients included are naïve to biological therapy and have newly diagnosed or relapsing GCA. Fifty patients are randomly assigned in a 1:1 ratio to receive either 300 mg secukinumab or placebo subcutaneously at baseline, weeks 1, 2 and 3, and every 4 weeks from week 4. Patients in both treatment arms receive a 26-week prednisolone taper regimen. The study consists of a maximum 6-week screening period, a 52-week treatment period (including the 26-week tapering), and an 8-week safety follow-up, with primary and secondary endpoint assessments at week 28. Patients who do not achieve remission by week 12 experience a flare after remission or cannot adhere to the prednisolone tapering will enter the escape arm and receive prednisolone at a dose determined by the investigator's clinical judgment. The blinded treatment is continued. Two optional imaging sub-studies are included (ultrasound and contrast-media enhanced magnetic resonance angiography [MRA]) to assess vessel wall inflammation and occlusion before and after treatment. The primary endpoint is the proportion of patients in sustained remission until week 28 in the secukinumab group compared to the proportion of patients in the placebo group. A Bayesian approach is applied. The trial design allows the first placebo-controlled data collection on the efficacy and safety of secukinumab in patients with GCA. ClinicalTrials.gov NCT03765788 . Registration on 5 December 2018, prospective registration, EudraCT number 2018-002610-12; clinical trial protocol number CAIN457ADE11C.
Sections du résumé
BACKGROUND
BACKGROUND
One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and maintenance of remission with the monoclonal anti-IL-17A antibody secukinumab. Inhibition of IL-17A could therefore represent a potential new therapeutic option for the treatment of GCA.
METHODS
METHODS
This is a randomized, parallel-group, double-blind, placebo-controlled, multi-center, phase II study in which patients, treating physicians, and the associated clinical staff as well as the sponsor clinical team are blinded. It is designed to evaluate efficacy and safety of secukinumab compared to placebo in combination with an open-label prednisolone taper regimen. Patients included are naïve to biological therapy and have newly diagnosed or relapsing GCA. Fifty patients are randomly assigned in a 1:1 ratio to receive either 300 mg secukinumab or placebo subcutaneously at baseline, weeks 1, 2 and 3, and every 4 weeks from week 4. Patients in both treatment arms receive a 26-week prednisolone taper regimen. The study consists of a maximum 6-week screening period, a 52-week treatment period (including the 26-week tapering), and an 8-week safety follow-up, with primary and secondary endpoint assessments at week 28. Patients who do not achieve remission by week 12 experience a flare after remission or cannot adhere to the prednisolone tapering will enter the escape arm and receive prednisolone at a dose determined by the investigator's clinical judgment. The blinded treatment is continued. Two optional imaging sub-studies are included (ultrasound and contrast-media enhanced magnetic resonance angiography [MRA]) to assess vessel wall inflammation and occlusion before and after treatment. The primary endpoint is the proportion of patients in sustained remission until week 28 in the secukinumab group compared to the proportion of patients in the placebo group. A Bayesian approach is applied.
DISCUSSION
CONCLUSIONS
The trial design allows the first placebo-controlled data collection on the efficacy and safety of secukinumab in patients with GCA.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03765788 . Registration on 5 December 2018, prospective registration, EudraCT number 2018-002610-12; clinical trial protocol number CAIN457ADE11C.
Identifiants
pubmed: 34404463
doi: 10.1186/s13063-021-05520-1
pii: 10.1186/s13063-021-05520-1
pmc: PMC8369438
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
secukinumab
DLG4EML025
Banques de données
ClinicalTrials.gov
['NCT03765788']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543Informations de copyright
© 2021. The Author(s).
Références
Ann Rheum Dis. 2017 May;76(5):898-905
pubmed: 27927642
Clin Rheumatol. 2012 Feb;31(2):231-7
pubmed: 21743987
Health Technol Assess. 2016 Nov;20(90):1-238
pubmed: 27925577
Ann Rheum Dis. 2013 Sep 1;72(9):1481-7
pubmed: 22993227
Value Health. 2017 Apr;20(4):644-650
pubmed: 28408007
Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S34-8
pubmed: 22410311
Arthritis Rheum. 2003 Oct 15;49(5):703-8
pubmed: 14558057
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Rheumatology (Oxford). 2018 Jun 1;57(6):982-986
pubmed: 29529280
Best Pract Res Clin Rheumatol. 2004 Oct;18(5):705-22
pubmed: 15454128
Ann Rheum Dis. 2018 May;77(5):636-643
pubmed: 29358285
Ann Intern Med. 2007 May 1;146(9):621-30
pubmed: 17470830
Rheumatology (Oxford). 2008 Sep;47(9):1406-8
pubmed: 18625659
RMD Open. 2018 Feb 2;4(1):e000612
pubmed: 29531788
Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S77-82
pubmed: 19646351
BMC Med. 2018 Jan 10;16(1):4
pubmed: 29316928
Qual Life Res. 2011 May;20(4):601-8
pubmed: 21063786
J Pain Symptom Manage. 1997 Feb;13(2):63-74
pubmed: 9095563
Ann Rheum Dis. 2010 Jul;69(7):1356-9
pubmed: 20498213
Rheumatology (Oxford). 2018 May 1;57(5):934-936
pubmed: 29394408
J Rheumatol. 2015 Jan;42(1):119-25
pubmed: 25362658
J Pharm Bioallied Sci. 2011 Jan;3(1):118-27
pubmed: 21430962
Autoimmun Rev. 2010 Aug;9(10):635-45
pubmed: 20457278
Lancet. 1995 Apr 1;345(8953):866
pubmed: 7898257
N Engl J Med. 2017 Jul 27;377(4):317-328
pubmed: 28745999
Drugs. 2021 Mar;81(4):483-494
pubmed: 33661486
Arthritis Rheum. 2002 May;46(5):1309-18
pubmed: 12115238
Arthritis Care Res (Hoboken). 2015 Mar;67(3):390-5
pubmed: 25132663
JAMA. 2016 Jun 14;315(22):2442-58
pubmed: 27299619
Ultraschall Med. 2013 Feb;34(1):47-50
pubmed: 22693039
Int J Rheumatol. 2013;2013:912562
pubmed: 23653652
Nat Rev Rheumatol. 2017 Oct;13(10):578-592
pubmed: 28905861
J Rheumatol. 2003 Oct;30(10):2177-81
pubmed: 14528514
Ann Rheum Dis. 2014 Sep;73(9):1742-5
pubmed: 24919468
Arthritis Res Ther. 2006;8(4):R116
pubmed: 16859533
Arthritis Rheum. 2012 Nov;64(11):3788-98
pubmed: 22833233
ACR Open Rheumatol. 2020 Feb;2(2):119-127
pubmed: 31957970
RMD Open. 2018 May 17;4(1):e000598
pubmed: 29862043
FEBS Lett. 1989 Jan 2;242(2):237-9
pubmed: 2464504
Dtsch Arztebl Int. 2013 May;110(21):376-85; quiz 386
pubmed: 23795218
Ann Intern Med. 2001 Jan 16;134(2):106-14
pubmed: 11177313
Pediatr Nephrol. 2010 Jun;25(6):1037-48
pubmed: 19844748
Arthritis Rheumatol. 2014 Feb;66(2):428-32
pubmed: 24504815
Ann Rheum Dis. 1986 Feb;45(2):136-8
pubmed: 3511861
Ann Rheum Dis. 2017 Mar;76(3):543-546
pubmed: 27474764
N Engl J Med. 1997 Nov 6;337(19):1336-42
pubmed: 9358127
Nat Rev Rheumatol. 2011 May;7(5):282-9
pubmed: 21468143
Autoimmun Rev. 2017 Aug;16(8):833-844
pubmed: 28564617